哮喘联盟

   摘要
   目的：严重职业性哮喘(OA)的治疗仍然存在问题，需要更好的疾病控制疗法。病情得到理想控制的患者仍然可以继续工作。
   方法：10例严重难控性OA患者接受IgE单克隆抗体奥马珠单抗的治疗。6例患者的致病因素是高分子复合物，4例患者是低分子化学物质。所有患者均明确罹患OA，即使更换工作场所。
   结果：治疗过程中，9例患者哮喘发作次数减少，口服或吸入糖皮质激素减量。7例患者可以在治疗前所在工作地点继续工作。
   结论：研究表明奥马珠单抗是严重的难控性OA的一种可能的治疗方案，它使本研究中10例患者中的7例得以继续他们的工作。

 

（刘国梁 审校）
Allergy. 2013 May 6. doi: 10.1111/all.12149. [Epub ahead of print]

Usefulness of omalizumab in ten patients with severe occupational asthma.
 

Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R, Mangiapan G, De Blay F.

Abstract
BACKGROUND: The management of severe occupational asthma (OA) remains problematic and new alternative treatments providing better disease control are required, ideally enabling affected individuals to remain in their job.
METHODS: Ten patients with severe uncontrolled OA were treated with the monoclonal anti-IgE antibody omalizumab. In six cases the causative agent was a high molecular weight (HMW) compound and in four cases it was a low molecular weight (LMW) chemical.All of the patients had well documented OA despite workplace adjustments.
RESULTS: During treatment, nine patients exhibited a lower rate of asthma exacerbations and used less oral or inhaled corticosteroids. Seven patients were able to continue working at the same workplace as before treatment.
CONCLUSION: We have demonstrated that omalizumab is a potential treatment for severe uncontrolled OA and enabled seven of the ten patients in the study to remain in their job.

Allergy. 2013 May 6. doi: 10.1111/all.12149. [Epub ahead of print]